Search results for "EMBER"

showing 10 items of 549 documents

Experimental and DFT studies on competitive heterocyclic rearrangements. part 2: A one-atom side-chain versus the classic three-atom side-chain (Boul…

2007

The experimental investigation of the base-catalyzed rearrangements of 3-acylamino-1,2,4-oxadiazoles evidenced a new reaction pathway which competes with the well-known ring-degenerate Boulton- Katritzky rearrangement (BKR). The new reaction consists of a one-atom side-chain rearrangement that is base-activated, occurs at a higher temperature than the BKR, and irreversibly leads to the corresponding 2-acylamino-1,3,4-oxadiazoles. An extensive DFT study is reported to elucidate the proposed reaction mechanism and to compare the three possible inherent routes: (i) the reversible three-atom side-chain ring-degenerate BKR, (ii) the ring contraction-ring expansion route (RCRE), and (iii) the one…

CASCADE REARRANGEMENTPHOTOCHEMICAL APPROACHDEGENERATE EQUILIBRATION124-OXADIAZOLE SERIESMONOCYCLIC REARRANGEMENT5-MEMBERED HETEROCYCLESEXPEDIENT ROUTEPHOTOINDUCED MOLECULAR-REARRANGEMENTSGENERALIZED SYNTHESISBASIS-SETS
researchProduct

Rapid identification and sorting of viable virus-reactive CD4+ and CD8+ T cells based on antigen-triggered CD137 expression

2008

Abstract Current methods for the detection and isolation of antigen-specific CD4 + and CD8 + T cells require the availability of peptide/MHC multimers or are restricted to cells that produce cytokines after antigen contact. Here we show that de novo cell surface expression of the TNF-receptor family member CD137 (4-1BB) identifies recently activated, but not resting, human CD4 + and CD8 + memory T cells. Maximum CD137 expression level is uniformly observed in both T-cell subsets at 24h after stimulation with antigen. In experiments with CMV and EBV-reactive T cells, we confirmed the specificity of CD137 expression by co-staining with peptide/HLA tetramers. Substantial proportions of CD137 +…

CD4-Positive T-LymphocytesHerpesvirus 4 HumanImmunologyCytomegalovirusStreptamerCD8-Positive T-LymphocytesLymphocyte ActivationViral Matrix ProteinsInterferon-gammaTumor Necrosis Factor Receptor Superfamily Member 9Interleukin 21HumansImmunology and AllergyCytotoxic T cellIL-2 receptorAntigen-presenting cellAntigens ViralCD40biologyImmunomagnetic SeparationCD28PhosphoproteinsNatural killer T cellAdoptive TransferMolecular biologyGene Expression Regulationbiology.proteinK562 CellsJournal of Immunological Methods
researchProduct

Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines.

2006

AbstractIn HLA-incompatible hematopoietic stem cell transplantation, alloreactive donor T cells recognizing recipient mismatch HLA cause severe graft-versus-host disease (GVHD). Strategies allowing the selective depletion of alloreactive T cells as well as the enhancement of graft-versus-malignancy immunity would be beneficial. We generated donor CD8 T-cell lines in vitro using allogeneic recipient cells mismatched at a single HLA class I allele or haplotype as stimulators. Recipient cells were obtained from acute myeloid leukemias, renal-cell carcinomas, and CD40L-induced B lymphoblasts. Resulting alloreactive T cells were activated by incubating day 21 T-cell cultures with HLA-mismatch tr…

CD4-Positive T-LymphocytesHerpesvirus 4 HumanIsoantigensT cellImmunologyCD40 LigandCytomegalovirusGraft vs Host DiseaseHuman leukocyte antigenBiologyCD8-Positive T-LymphocytesIn Vitro TechniquesLymphocyte ActivationTransfectionBiochemistryImmunotherapy AdoptiveLymphocyte DepletionTumor Necrosis Factor Receptor Superfamily Member 9AntigenHLA AntigensT-Lymphocyte SubsetsmedicineCytotoxic T cellHumansCarcinoma Renal CellCells CulturedSkinB-LymphocytesImmunomagnetic SeparationLymphoblastCD137Cell BiologyHematologyT lymphocyteFibroblastsCytotoxicity Tests ImmunologicKidney Neoplasmsmedicine.anatomical_structureLeukemia MyeloidHistocompatibilityImmunologyK562 CellsCD8Blood
researchProduct

Activity of the dietary flavonoid, apigenin, against multidrug-resistant tumor cells as determined by pharmacogenomics and molecular docking

2015

Apigenin is a common dietary flavonoid with considerable cytotoxic activity in vitro and in vivo. Despite many mechanistic studies, less is known about resistance factors hampering apigenin's activity. We investigated the ATP-binding cassette (ABC) transporters BCRP/ABCG2, P-glycoprotein/ABCB1 and its close relative ABCB5. Multidrug-resistant cells overexpressing these ABC transporters were not cross-resistant toward apigenin. Moreover, apigenin inhibited not only P-glycoprotein but also BCRP by increasing cellular uptake of doxorubicin and synergistic inhibition of cell viability in combination with doxorubicin or docetaxel in multidrug-resistant cells. To perform in silico molecular docki…

Cancer ResearchAbcg2Protein ConformationEndocrinology Diabetes and MetabolismClinical BiochemistryATP-binding cassette transporterPharmacologyBiochemistryMicechemistry.chemical_compoundTranscriptional regulationCluster AnalysisImmunology and AllergyApigeninNutrition and DieteticsbiologyABCB5Drug Resistance MultipleNeoplasm ProteinsMolecular Docking SimulationOncologyBiochemistryApigeninMolecular Medicinemedicine.drugIn silicoImmunologyInhibitory Concentration 50Cell Line TumormedicineAnimalsHumansDoxorubicinATP Binding Cassette Transporter Subfamily B Member 1RNA MessengerViability assayMolecular BiologyPharmacologyComputational BiologyPolyphenolsTransporterIn vitroHEK293 CellschemistryDoxorubicinDrug Resistance NeoplasmPharmacogeneticsPoster Presentationbiology.proteinATP-Binding Cassette TransportersThe Journal of Nutritional Biochemistry
researchProduct

Patterns of Innate or Acquired Resistance to Anticancer Drugs: Our Experience to Overcome It

2021

Drug resistance, which is often of a multiple type, can be defined as the ability of cancer cells to obtain resistance to both conventional and novel chemotherapy agents. It remains a major problem to solve in cancer therapy. The mechanisms of resistance are multifactorial, and in our cellular models of acute myeloid leukemia, hepatocellular carcinoma, and triple-negative breast cancer, it involves the NF-κB pathway. In our opinion, multitarget molecules can be considered as privileged compounds capable of attacking and reversing the resistant phenotype. In the phenomena of both innate and acquired drug resistance that we have been studying since 1998 to today and up to 2016 under the guida…

Cancer ResearchAntineoplastic AgentsApoptosisPhosphatidylethanolamine Binding ProteinDrug resistanceMetastasisBreast cancerdrug resistance P-glycoprotein IAP NF-κBNeoplasmsHumansMedicineATP Binding Cassette Transporter Subfamily B Member 1Transcription factorYY1 Transcription FactorP-glycoproteinbiologybusiness.industryKinaseNF-kappa BMyeloid leukemiamedicine.diseaseDrug Resistance NeoplasmCancer cellSettore BIO/14 - Farmacologiabiology.proteinCancer researchbusinessCritical Reviews™ in Oncogenesis
researchProduct

Antioxidant defenses in a B16 melanoma line resistant to doxorubicin: an in vivo study.

1991

A B16 melanoma line was repeatedly transplanted subcutaneously in C57BL/6 mice. On day 4 after every transplant, the animals were treated with doxorubicin (DXR), 10 mg/kg i.p. The aim of the work was to develop an in-vivo model of resistance to the antiblastic in order to analyze some possible mechanistic aspects of the process in the course of time. After 16 transplants and treatments the melanoma completely lost its sensitivity to the antiproliferative effects of maximal tolerated doses of DXR and showed over-expression of P-glycoprotein. Compared to the parental line, the in vitro resistance index was 4.6. After 27 transplants and treatments the melanoma did not increase its in vitro res…

Cancer ResearchAntioxidantmedicine.medical_treatmentGlutathione reductaseDrug ResistanceMelanoma ExperimentalPharmacologySuperoxide dismutasechemistry.chemical_compoundMiceIn vivoTumor Cells CulturedMedicineAnimalsPharmacology (medical)DoxorubicinATP Binding Cassette Transporter Subfamily B Member 1Pharmacologychemistry.chemical_classificationMembrane Glycoproteinsbiologybusiness.industryMelanomaGlutathione peroxidaseGlutathionemedicine.diseaseGlutathioneImmunohistochemistryMice Inbred C57BLOncologychemistryDoxorubicinVincristinebiology.proteinFemalebusinessNeoplasm Transplantationmedicine.drugAnti-cancer drugs
researchProduct

Selective induction of apoptosis in multidrug resistant HL60R cells by the thiazolobenzoimidazole derivative 1-(2,6-difluorophenyl)-1H,3H-thiazolo [3…

1999

We investigated the antitumour effects of 1-(2,6-difluorophenyl)-1H,3H-thiazolo [3,4-a]benzimidazole (TBZ) a new anti-HIV-1 agent, on human promyelocytic HL60 leukaemia, both a parental and a multidrug resistant form (HL60R). HL60R overexpresses P-glycoprotein and, like HL60, lacks p53 protein expression. HL60 and HL60R show similar levels of Bcl-2 protein. In contrast to the conventional chemotherapeutic agents daunorubicin, etoposide and mitoxantrone, TBZ caused equal or even greater cytotoxicity in HL60R than in HL60, and this result was associated with a more marked induction of apoptosis in the drug resistant cells. The antitumour activity of TBZ occurred in the range of concentrations…

Cancer ResearchBenzimidazoleAnti-HIV AgentsDaunorubicinHL60ApoptosisHL-60 CellsDrug resistancePharmacologychemistry.chemical_compoundmedicineHumansATP Binding Cassette Transporter Subfamily B Member 1CytotoxicityP-glycoproteinbiologyFlow CytometryVirologyDrug Resistance MultipleMultiple drug resistanceThiazolesProto-Oncogene Proteins c-bcl-2OncologychemistryDrug Resistance NeoplasmApoptosisbiology.proteinBenzimidazolesDrug Screening Assays AntitumorTumor Suppressor Protein p53medicine.drugEuropean Journal of Cancer
researchProduct

Resistance to diverse apoptotic triggers in multidrug resistant HL60 cells and its possible relationship to the expression of P-glycoprotein, Fas and…

2002

We studied the human HL60 leukemia cell line and its multidrug resistant (MDR) variant HL60R. In contrast to the HL60, HL60R showed an inability to undergo apoptosis from doxorubicin (Dox) or other different stimuli, including cisplatin, Fas ligation and serum withdrawal. HL60R cells lost surface Fas expression, but we found no evidence that Fas/FasL mediates the apoptotic effects of Dox in HL60. P-glycoprotein (P-gp) did not seem to play a major role as a specific inhibitor of apoptosis. In fact, the P-gp inhibitor verapamil reversed only partially the resistance to Dox-induced apoptosis of the MDR cells. In addition, it did not modify the rate of apoptosis induced from the other stimuli i…

Cancer ResearchProgrammed cell deathTime FactorsChromosomal Proteins Non-HistoneSurvivinDown-RegulationAntineoplastic AgentsApoptosisHL-60 CellsNerve Tissue ProteinsBiologyInhibitor of apoptosisFas ligandInhibitor of Apoptosis ProteinsInhibitory Concentration 50SurvivinTumor Cells CulturedHumansATP Binding Cassette Transporter Subfamily B Member 1RNA Messengerfas ReceptorP-glycoproteinInhibitor of apoptosis domainCaspase 3Reverse Transcriptase Polymerase Chain ReactionProteinsFlow CytometryNeuronal Apoptosis-Inhibitory ProteinNeoplasm ProteinsCell biologyProto-Oncogene Proteins c-bcl-2OncologyDoxorubicinDrug Resistance NeoplasmApoptosisCaspasesbiology.proteinInsect ProteinsNAIPCisplatinMicrotubule-Associated ProteinsCancer Letters
researchProduct

High frequency of a non-functional TAP1/LMP2 promoter polymorphism in human tumors

2002

The Tap1 and Tap2 genes encoding for a heterodimeric peptide transporter play a key role in antigen processing and presentation. The TAP complex mediates the transport of peptides generated by the IFN-gamma-inducible proteasome subunits LMP2, 7 and 10 from the cytosol into the endoplasmic reticulum (ER), where they bind to MHC class I molecules. In contrast to the frequent polymorphisms within the rat Tap genes which exert functional differences, polymorphic regions within the human Tap genes have been demonstrated, but not systematically analyzed in terms of their functional significance. Both the Tap1 and Lmp2 genes are transcribed from a bidirectional intergenic promoter which is regulat…

Cancer ResearchTransfectionViral Matrix ProteinsIntergenic regionGene FrequencyGenotypeMHC class ITumor Cells CulturedAnimalsHumansRNA MessengerATP Binding Cassette Transporter Subfamily B Member 2Promoter Regions GeneticCarcinoma Renal CellMelanomaGeneGeneticsPolymorphism GeneticbiologyReverse Transcriptase Polymerase Chain ReactionAntigen processingEndoplasmic reticulumMolecular biologyGene Expression Regulation NeoplasticOncologyCOS Cellsbiology.proteinTAP2ATP-Binding Cassette TransportersTAP1International Journal of Oncology
researchProduct

Role of the tumor microenvironment in the activity and expression of the p-glycoprotein in human colon carcinoma cells.

2006

The metabolic microenvironment of solid tumors is characterized by an oxygen deficiency and increased anaerobic glycolysis leading to extracellular acidosis and ATP depletion, which in turn may affect other energy-dependent cellular pathways. Since many tumors overexpress active drug transporters (e.g. the p-glycoprotein) leading to a multidrug-resistant phenotype, this study analyzes the impact of the different aspects of the extracellular microenvironment (hypoxia and acidosis) on the activity and expression of the p-glycoprotein (pGP) in the human colon carcinoma cell line LS513. For up to 24 h cells were exposed to hypoxia (pO2<0.5 mmHg), an acidic extracellular environment (pH 6.6), or…

Cancer Researchmedicine.medical_specialtyIntracellular pHInternal medicineCell Line TumormedicineExtracellularHumansATP Binding Cassette Transporter Subfamily B Member 1P-glycoproteinAcidosisTumor microenvironmentbiologyDaunorubicinBiological activityGeneral MedicineHydrogen-Ion ConcentrationCell HypoxiaEndocrinologyOncologyAnaerobic glycolysisbiology.proteinCancer researchEffluxmedicine.symptomAcidosisColorectal NeoplasmsOncology reports
researchProduct